Timolol Maleate Gel for the Treatment of Infantile Hemangioma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

June 21, 2022

Study Completion Date

June 21, 2022

Conditions
Infantile Hemangioma
Interventions
DRUG

Timolol Maleate Gel+Placebo

Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.

DRUG

Timolol Maleate Gel

Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.

DRUG

Placebo

Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.

Trial Locations (8)

100045

Beijing Children's Hospital,Capital Medical University, Beijing

100056

Children's Hospital, Capital Institute of Pediatrics, Beijing

200011

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

200080

Chengdu Women's and Children's Central Hospital, Chengdu

215025

Children's Hospital of Soochow University, Suzhou

310052

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

650228

Kunming Children's Hospital, Kunming

030013

Children's Hospital of Shanxi, Taiyuan

Sponsors
All Listed Sponsors
lead

Auson Pharmaceuticals Inc.

INDUSTRY